<p>MapLight Therapeutics Inc. reported its third quarter (Q3) 2025 financial results. Research and development expenses for Q3 2025 totaled USD 27.1 million, an increase of 61 percent, primarily driven by higher clinical trial, employee-related, and formulation and CMC expenses. General and administrative expenses for the period were USD 4.4 million. Total operating expenses reached USD 31.5 million for Q3 2025. Net loss for the quarter was USD 29.4 million. For the nine-month period ended September 30, 2025, research and development expenses were USD 73.7 million and general and administrative expenses were USD 12.0 million. Total operating expenses for the nine-month period amounted to USD 85.7 million. The company also reported that it raised USD 296.5 million in gross proceeds from its initial public offering and concurrent private placement in October 2025, and that cash, cash equivalents, and short-term investments are sufficient to fund operations through 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596649-en) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

MPLT

<p>MapLight Therapeutics Inc. reported a Q3 2025 net loss of USD 29.4 million, up 55%. Research and development expenses increased by 61% to USD 27.1 million, while general and administrative expenses were USD 4.4 million. Total operating expenses for Q3 reached USD 31.5 million. The company raised USD 296.5 million from its IPO and private placement, ensuring funding through 2027.</p>

MapLight Therapeutics Inc. Q3 net loss rises to USD 29.4 million, up 55 percent